Edwards Lifesciences Corporation
EW · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $44,248 | $46,261 | $46,184 | $80,749 |
| - Cash | $3,045 | $1,132 | $769 | $863 |
| + Debt | $700 | $685 | $691 | $690 |
| Enterprise Value | $41,903 | $45,814 | $46,106 | $80,576 |
| Revenue | $5,440 | $5,010 | $5,382 | $5,233 |
| % Growth | 8.6% | -6.9% | 2.9% | – |
| Gross Profit | $4,322 | $3,973 | $4,215 | $4,007 |
| % Margin | 79.5% | 79.3% | 78.3% | 76.6% |
| EBITDA | $1,723 | $1,535 | $1,960 | $1,890 |
| % Margin | 31.7% | 30.6% | 36.4% | 36.1% |
| Net Income | $4,175 | $1,402 | $1,522 | $1,503 |
| % Margin | 76.7% | 28% | 28.3% | 28.7% |
| EPS Diluted | 6.97 | 2.3 | 2.44 | 2.38 |
| % Growth | 203% | -5.7% | 2.5% | – |
| Operating Cash Flow | $542 | $896 | $1,218 | $1,732 |
| Capital Expenditures | -$252 | -$266 | -$265 | -$330 |
| Free Cash Flow | $290 | $630 | $953 | $1,402 |